المؤلفون: T. Kirsanova V., A. Balakireva I., T. Fedorova A., Т. Кирсанова В., А. Балакирева И., Т. Федорова А.

المصدر: Meditsinskiy sovet = Medical Council; № 13 (2021); 128-137 ; Медицинский Совет; № 13 (2021); 128-137 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: HELLP syndrome, hemolytic uremic syndrome, acute kidney injury, thrombotic microangiopathies, pregnancy, HELLP-синдром, гемолитико-уремический синдром, острое повреждение почек, тромботические микроангиопатии, беременность

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/6408/5799; Rao S., Jim B. Acute Kidney Injury in Pregnancy: The Changing Landscape for the 21st Century. Kidney Int Rep. 2018;3(2):247–257. https://doi.org/10.1016/j.ekir.2018.01.011.; Naqvi R. Hemolytic Uremic syndrome associated with pregnancy: Outcome from acute Kidney Injury. Pak J Med Sci. 2020;36(6):1153–1157. https://doi.org/10.12669/pjms.36.6.2931.; Haroon F., Murtaza F., Dhrolia Qureshi R., Imtiaz S., Ahmed A. Frequency of Pregnancy-Related Complications Causing Acute Kidney Injury in Pregnant Patients at a Tertiary Care Hospital. Saudi J Kidney Dis Transpl. 2019;30(1): 194–201. Available at: https://www.sjkdt.org/text.asp?2019/30/1/194/252910.; Bruel A., Kavanagh D., Norris M., Delmas Y., Wong E.K., Bresin E. et al. Hemolytic Uremic Syndrome in Pregnancy and Postpartum. Clin J Am Soc Nephrol. 2017;12(8):1237–1247. Available at: https://doi.org/10.2215/CJN.00280117.; Zafrani L., Mariotte E., Darmon M., Canet E., Merceron S., Boutboul D. et al. Acute renal failure is prevalent in patients with thrombotic thrombocytopenic purpura associated with low plasma ADAMTS13 activity. J Thromb Haemost. 2015;13(3):380–389. https://doi.org/10.1111/jth.12826.; Erdemoğlu M., Kuyumcuoğlu U., Kale A., Akdeniz N. Factors affecting maternal and perinatal outcomes in HELLP syndrome: evaluation of 126 cases. Clin Exp Obstet Gynecol. 2019;37(3):213–216. Available at: https://ceog.imrpress.com/EN/Y2010/V37/I3/213.; Gedik E., Yücel N., Sahin T., Koca E., Colak Y.Z., Togal T. Hemolysis, elevated liver enzymes, and low platelet syndrome: Outcomes for patients admitted to intensive care at a tertiary referral hospital. Hypertens Pregnancy. 2017;36(1):21–29. https://doi.org/10.1080/10641955.2016.1218505.; Sibai B.M., Ramadan M.K., Usta I., Salama M., Mercer B.M., Friedman S.A. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol. 1993;169(4):1000–1006. https://doi.org/10.1016/0002-9378(93)90043-i.; Gul A., Aslan H., Cebeci A., Polat I., Ulusoy S., Ceylan Y. Maternal and fetal outcomes in HELLP syndrome complicated with acute renal failure. Renal Fail. 2004;26(5):557–562. https://doi.org/10.1081/jdi-200031750.; Martínez de Ita A.L., García Cáceres E., Helguera Martínez A.M., Cejudo Carranza E. Acute renal insufficiency in HELLP syndrome. Ginecol Obstet Mex. 1998;66:462–468. Available at: https://pubmed.ncbi.nlm.nih.gov/9823704/.; Abraham K.A., Connolly G., Farrell J., Walshe J.J. The HELLP syndrome, a prospective study. Renal Fail. 2001;23(5):705–713. https://doi.org/10.1081/jdi-100107367.; Huang C., Chen S. Acute kidney injury during pregnancy and puerperium: a retrospective study in a single center. BMC Nephrol. 2017;18(1):146. https://doi.org/10.1186/s12882-017-0551-4.; Selçuk N.Y., Odabas A.R., Cetinkaya R., Tonbul H.Z., San A. Outcome of pregnancies with HELLP syndrome complicated by acute renal failure (1989– 1999). Renal Fail. 2000;22(3):319–327. https://doi.org/10.1081/jdi-100100875.; Drakeley A.J., Le Roux P.A., Anthony J., Penny J. Acute renal failure complicating severe preeclampsia requiring admission to an obstetric intensive care unit. Am J Obstet Gynecol. 2002;186(2):253–256. https://doi.org/10.1067/mob.2002.120279.; American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20(6):864–874. Available at: https://pubmed.ncbi.nlm.nih.gov/1597042.; Prakash J., Pant P., Prakash S., Sivasankar M., Vohra R., Doley P.K. Changing picture of acute kidney injury in pregnancy: Study of 259 cases over a period of 33 years. Indian J Nephrol. 2016;26(4):262–267. https://doi.org/10.4103/0971-4065.161018.; Prakash J., Ganiger V.C. Acute Kidney Injury in Pregnancy-specific Disorders. Indian J Nephrol. 2017;27(4):258–270. https://doi.org/10.4103/0971-4065.202406.; Птушкин В.В., Кулагин А.Д., Лукина Е.А., Давыдкин И.Л., Константинова Т.С., Шамрай В.С. и др. Результаты открытого многоцентрового клинического исследования Ib фазы по оценке безопасности, фармакокинетики и фармакодинамики первого биоаналога экулизумаба у нелеченых пациентов с пароксизмальной ночной гемоглобинурией в фазе индукции терапии. Терапевтический архив. 2020;92(7):77–84. https://doi.org/10.26442/00403660.2020.07.000818.; Kulagin A., Ptushkin V., Lukina E., Gapchenko E., Markova O., Zuev E., Kudlay D. Phase III clinical trial of Elizaria® and Soliris® in adult patients with paroxysmal nocturnal hemoglobinuria: results of comparative analysis of efficacy, safety, and pharmacological data. Blood. 2019;134(1 Suppl.):3748. https://doi.org/10.1182/blood-2019-125693.; Kulagin A., Ptushkin V., Lukina E., Davydkin I., Korobkin A., Shamrai V. et al. Randomized multicenter noninferiority phase III clinical trial of the first biosimilar of eculizumab. Ann Hematol. 2021. https://doi.org/10.1007/s00277-021-04624-7.; Кирсанова Т.В., Виноградова М.А., Колыванова А.И., Шмаков Р.Г. HELLPсиндром: клинико-лабораторные особенности и дисбаланс плацентарных факторов ангиогенеза. Акушерство и гинекология. 2018;(7):46–55. https://doi.org/10.18565/aig.2018.7.46-55.; Коротчаева Ю.В., Козловская Н.Л., Шифман Е.М., Демьянова К.А. Поздние осложнения беременности как триггеры акушерского атипичного гемолитико уремического синдрома. Нефрология и диализ. 2020;22(2):198–209. https://doi.org/10.28996/2618-9801-2020-2-198-209.; Sabau L., Terriou L., Provot F., Fourrier F., Roumier C., Caron C. et al. Are there any additional mechanisms for haemolysis in HELLP syndrome? Thrombosis Res. 2016;142:40–43. https://doi.org/10.1016/j.thromres.2016.03.014.; Sibai B.M., Barton J.R. Expectant management of severe preeclampsia remote from term: patient selection, treatment, and delivery indications. Am J Obstet Gynecol. 2007;196(6):514.e1–514.e9. https://doi.org/10.1016/j.ajog.2007.02.021.; Randeree I.G., Czarnocki A., Moodley J., Seedat Y.K., Naiker I.P. Acute renal failure in pregnancy in South Africa. Renal Fail. 1995;17(2):147–153. https://doi.org/10.3109/08860229509026251.; Sibai B.M., Ramadan M.K. Acute renal failure in pregnancies complicated by hemolysis, elevated liver enzymes, and low platelets. Am J Obstet Gynecol. 1993;168(6):1682–1690. https://doi.org/10.1016/0002-9378(93)90678-c.; Vesely S.K., George J.N., Lämmle B., Studt J.D., Alberio L., El-Harake M.A., Raskob G.E. ADAMTS13 activity in thrombotic thrombocytopenic purpurahemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003;102(1):60–68. https://doi.org/10.1182/blood-2003-01-0193.; Raife T., Atkinson B., Montgomery R., Vesely S., Friedman K. Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients. Transfusion. 2004;44(2):146–150. https://doi.org/10.1111/j.1537-2995.2004.00626.x.; Zheng X.L., Kaufman R.M., Goodnough L.T., Sadler J.E. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood. 2004;103(11):4043–4049. https://doi.org/10.1182/blood-2003-11-4035.; Coppo P., Bengoufa D., Veyradier A., Wolf M., Bussel A., Millot G.A. et al. Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore). 2004;83(4):233–244. https://doi.org/10.1097/01.md.0000133622.03370.07.; Nair R.K., Khaira A., Sharma A., Mahajan S., Dinda A.K. Spectrum of renal involvement in paroxysmal nocturnal hemoglobinuria: report of three cases and a brief review of the literature. Int Urol Nephrol. 2008;40(2):471–475. https://doi.org/10.1007/s11255-008-9356-5.; Hothi D.K., Bass P., Morgan M., Acharya J., Humphries S.E., Gilbert R.D. Acute renal failure in a patient with paroxysmal cold hemoglobinuria. Pediatr Nephrol. 2007;22(4):593–596. https://doi.org/10.1007/s00467-006-0352-7.; Pollard T.D., Weiss I.W. Acute tubular necrosis in a patient with march hemoglobinuria. N Engl J Med. 1970;283(15):803–804. https://doi.org/10.1056/NEJM197010082831509.; Qian Q., Nath K.A., Wu Y., Daoud T.M., Sethi S. Hemolysis and acute kidney failure. Am J Kidney Dis. 2010;56(4):780–784. https://doi.org/10.1053/j.ajkd.2010.03.025.; Ye W., Shu H., Yu Y., Li H., Chen L., Liu J., Li X.M. Acute kidney injury in patients with HELLP syndrome. Int Urol Nephrol. 2019;51(7):1199–1206. https://doi.org/10.1007/s11255-019-02111-7.; https://www.med-sovet.pro/jour/article/view/6408

الاتاحة: https://www.med-sovet.pro/jour/article/view/6408
https://doi.org/10.21518/2079-701X-2021-13-128-137

المؤلفون: T. Kirsanova V., M. Vinogradova A., Т. Кирсанова В., М. Виноградова А.

المصدر: Meditsinskiy sovet = Medical Council; № 3 (2021); 98-105 ; Медицинский Совет; № 3 (2021); 98-105 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: thrombotic microangiopathy, HELLP syndrome, atypical hemolytic-uremic syndrome, thrombocytopenic purpura, eculizumab, тромботическая микроангиопатия, HELLP-синдром, атипичный гемолитико-уремический синдром, тромбоцитопеническая пурпура, экулизумаб

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/6079/5539; Fakhouri F., Zuber J., Fremeaux-Bacchi V., Loirat C. Haemolytic uraemic syndrome. Lancet. 2017;390(10095):681-696. doi:10.1016/S0140-6736(17)30062-4.; George J.N., Nester C.M., McIntosh JJ. Syndromes of thrombotic microangiopathy associated with pregnancy. Hematology Am Soc Hematol Educ Program. 2015;2015:644-648. doi:10.1182/asheducation-2015.1.644.; George J.N., Nester C.M. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371(7):654-666. doi:10.1056/NEJMra1312353.; Кирсанова Т.В., Виноградова М.А., Федорова ТА. Имитаторы тяжелой преэклампсии и HELL-синдрома: различные виды тромботической микроангиопатии, ассоциированной с беременностью. Акушерство и гинекология. 2016;(12):5-14 doi:10.18565/aig.2016.12.5-14.; Brown M.A., Magee L.A., Kenny L.C., Karumanchi S.A., McCarthy F.P., Saito S. et al. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension. 2018;72(1):24-43. doi:10.1161/HYPERTENSIONAHA.117.10803.; Mol B.W. J., Roberts C.T., Thangaratinam S., Magee L.A., de Groot CJ.M., Hofmeyr GJ. Preeclampsia. Lancet. 2016;387(10022):999-1011. doi:10.1016/S0140-6736(15)00070-7.; Liu J., Ghaziani T.T., Wolf J.L. Acute fatty liver disease of pregnancy: updates in pathogenesis, diagnosis, and management. Am J Gastroenterol. 2017;112(6):838-846. doi:10.1038/ajg.2017.54.; Silver R.M. Catastrophic antiphospholipid syndrome and pregnancy. Semin Perinatol. 2018;42(1):26-32. doi:10.1053/j.semperi.2017.11.006.; Burlinson C.E. G., Sirounis D., Walley K.R., Chau A. Sepsis in pregnancy and the puerperium. Int J Obstet Anesth. 2018;36:96-107. doi:10.1016/j.ijoa.2018.04.010.; Fakhouri F., Scully M., Provot F., Blasco M., Coppo P, Noris M. et al. Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. Blood. 2020;136(19):2103-2117. doi:10.1182/blood.2020005221.; Kellum J.A., Aspelin P., Barsoum R.S., Burdmann E.A., Goldstein S.L., Herzog C.A. et al. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(1):1-138. Available at: https://Www.kisupple-ments.org/issue/S2157-1716(12)X7200-9.; Fujimura Y., Matsumoto M. Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara Medical University during 19982008. Intern Med. 2010;49(1):7-15. doi:10.2169/internalmedicine.49.2706.; Mariotte E., Azoulay E., Galicier L., Rondeau E., Zouiti F., Boisseau P et al. Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. Lancet Haematol. 2016;3(5):e237-e245. doi:10.1016/S2352-3026(16)30018-7.; Zheng X.L., Vesely S.K., Cataland S.R., Coppo P, Geldziler B., Iorio A. et al. ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020;18(10):2486-2495. doi:10.1111/jth.15006.; Mackie I., Mancini I., Muia J., Kremer Hovinga J., Nair S., Machin S., Baker R. International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of ADAMTS13. Int J Lab Hematol. 2020;42(6):685-696. doi:10.1111/ijlh.13295.; Moatti-Cohen M., Garrec C., Wolf M., Boisseau P, Galicier L., Azoulay E. et al. Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood. 2012;119(24):5888-5897. doi:10.1182/blood-2012-02-408914.; Delmas Y., Helou S., Chabanier P., Ryman A., Pelluard F., Carles D. et al. Incidence of obstetrical thrombotic thrombocytopenic purpura in a retrospective study within thrombocytopenic pregnant women. A difficult diagnosis and a treatable disease. BMC Pregnancy Childbirth. 2015;15(1):137. doi:10.1186/s12884-015-0557-5.; Lattuada A., Rossi E., Calzarossa C., Candolfi R., Mannucci P.M. Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haematologica. 2003;88(9):1029-1034. Available at: https://pub-med.ncbi.nlm.nih.gov/12969811/.; Stepanian A., Cohen-Moatti M., Sanglier T., Legendre P, Ameziane N., Tsatsaris V. et al. Von Willebrand factor and ADAMTS13: a candidate couple for preeclampsia pathophysiology. Arterioscler Thromb Vasc Biol. 2011;31(7):1703-1709. doi:10.1161/ATVBAHA.111.223610.; Bayer G., von Tokarski F., Thoreau B., Bauvois A., Barbet C., Cloarec S. et al. Etiology and outcomes of thrombotic microangiopathies. Clin J Am Soc Nephrol. 2019;14(4):557-566. doi:10.2215/CJN.11470918.; Bruel A., Kavanagh D., Noris M., Delmas Y., Wong E.K. S., Bresin E. et al. Hemolytic uremic syndrome in pregnancy and postpartum. Clin J Am Soc Nephrol. 2017;12(8):1237-1247. doi:10.2215/CJN.00280117.; Fakhouri F., Roumenina L., Provot F., Sallee M., Caillard S., Couzi L. et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol. 2010;21(5):859-886. doi:10.1681/ASN.2009070706.; Huerta A., Arjona E., Portoles J., Lopez-Sanchez P, Rabasco C., Espinosa M. et al. A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome. Kidney Int. 2018;93(2):450-459. doi:10.1016/j.kint.2017.06.022.; Rehberg J.F., Briery C.M., Hudson W.T., Bofill J.A., Martin J.N. Jr. Thrombotic thrombocytopenic purpura masquerading as hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome in late pregnancy. Obstet Gynecol. 2006;108(3 Pt. 2):817-820. doi:10.1097/01.AOG.0000215994.25958.31.; Птушкин В.В., Кулагин А.Д., Лукина Е.А., Давыдкин И.Л., Константинова Т.С., Шамрай В.С. и др. Результаты открытого многоцентрового клинического исследования Ib фазы по оценке безопасности, фармакокинетики и фармакодинамики первого биоаналога экулизумаба у нелеченых пациентов с пароксизмальной ночной гемоглобинурией в фазе индукции терапии. Терапевтический архив. 2020;92(7):77-84. doi:10.26442/00403660.2020.07.000818.; Kulagin A., Ptushkin V., Lukina E., Gapchenko E., Markova O., Zuev E., Kudlay D. Phase III clinical trial of Elizaria® and Soliris® in adult patients with paroxysmal nocturnal hemoglobinuria: results of comparative analysis of efficacy, safety, and pharmacological data. Blood. 2019;134(1 Suppl.):3748. doi:10.1182/blood-2019-125693.; Pourrat O., Coudroy R., Pierre F. ADAMTS13 deficiency in severe postpartum HELLP syndrome. Br J Haematol. 2013;163(3):409-410. doi:10.1111/bjh.12494.; Zeisler H., Llurba E., Chantraine F., Vatish M., Staff A.C., Sennstrom M. et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med. 2016;374(1):13-22. doi:10.1056/NEJMoa1414838.; Verlohren S., Herraiz I., Lapaire O., Schlembach D., Zeisler H., Calda P. et al. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension. 2014;63(2):346-352. doi:10.1161/HYPERTENSIONAHA.113.01787.; Caillon H., Tardif C., Dumontet E., Winer N., Masson D. Evaluation of sFlt-1/ PlGF ratio for predicting and improving clinical management of preeclampsia: experience in a specialized perinatal care center. Ann Lab Med. 2018;38(2):95-101. doi:10.3343/alm.2018.38.2.95.; George J.N. Cobalamin C deficiency-associated thrombotic microangiopathy: uncommon or unrecognised? Lancet. 2015;386(9997):1012. doi:10.1016/S0140-6736(15)00077-X.; Frimat M., Decambron M., Lebas C., Moktefi A., Lemaitre L., Gnemmi V. et al. Renal cortical necrosis in postpartum hemorrhage: a case series. Am J Kidney Dis. 2016;68(1):50-57. doi:10.1053/j.ajkd.2015.11.022.; Fakhouri F., Deltombe C. Pregnancy-related acute kidney injury in high income countries: still a critical issue. J Nephrol. 2017;30(6):767-771. doi:10.1007/s40620-017-0440-8.; Scully M., Thomas M., Underwood M., Watson H., Langley K., Camilleri R.S. et al. Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes. Blood. 2014;124(2):211-219. doi:10.1182/blood-2014-02-553131.; Fremeaux-Bacchi V, Fakhouri F., Garnier A., Bienaime F., Dragon-Durey MA., Ngo S. et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8(4):554-562. doi:10.2215/CJN.04760512.; Noris M., Caprioli J., Bresin E., Mossali C., Pianetti G., Gamba S. et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5(10):1844-1859. doi:10.2215/CJN.02210310.; https://www.med-sovet.pro/jour/article/view/6079

الاتاحة: https://www.med-sovet.pro/jour/article/view/6079
https://doi.org/10.21518/2079-701X-2021-3-98-105

المؤلفون: M. Vinogradova A., T. Kirsanova V., D. Serebriyskaya S., М. Виноградова А., Т. Кирсанова В., Д. Серебрийская С.

المصدر: Meditsinskiy sovet = Medical Council; № 3 (2020); 68-73 ; Медицинский Совет; № 3 (2020); 68-73 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2020-3

مصطلحات موضوعية: endothelial dysfunction, sulodexide, reproductive losses, chronic venous disease, pregravid preparation, дисфункция эндотелия, сулодексид, репродуктивные потери, хроническая венозная болезнь, прегравидарная подготовка

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/5572/5076; Черняховская Н.Е., Шишло В.К., Поваляев А.В. Коррекция микроциркуляции в клинической практике. М.: Бином; 2013. 208 с.; Cicinelli E., De Ziegler D., Nicoletti R., Colafiglio G., Saliani N., Resta L. et al. Chronic endometritis: correlation among hysteroscopic, histologic, and bacteriologic findings in a prospective trial with 2190 consecutive office hysteroscopies. Fertil Steril. 2008;89(3):677–684. doi:10.1016/j.fertnstert.2007.03.074.; Kimura F., Takebayashi A., Ishida M., Nakamura A., Kitazawa J., Morimune A. et al. Review: Chronic endometritis and its effect on reproduction. J Obstet Gynaecol Res. 2019;45(5):951–960. doi:10.1111/jog.13937.; Hoppensteadt D.A., Fareed J. Pharmacological profile of sulodexide. Int Angiol. 2014;33(3):229–235. Available at: https://www.ncbi.nlm.nih.gov/pubmed/24936531.; Masola V., Zaza G., Onisto M., Lupo A., Gambaro G. Glycosaminoglycans, proteoglycans and sulodexide and the endothelium: biological roles and pharmacological effects. Int Angiol. 2014;33:243–254. Available at: https://www.ncbi.nlm.nih.gov/pubmed/24936533.; Zhang X., Sun D., Song J.W., Zullo J., Lipphardt M., Coneh-Gould L., Goligorsky M.S. Endothelial cell dysfunction and glycocalyx – A viscious circle. Matrix Biol. 2018;71–72:421–431. doi:10.1016/j.matbio.2018.01.026.; Veraldi N., Guerrini M., Urso E., Risi G., Bertini S., Bensi D., Bisio A. Fine structural characterization of sulodexide. J Pharm Biomed Anal. 2018;156:67–79. doi:10.1016/j.jpba.2018.04.012.; Coccheri S., Mannello F. Development and use of sulodexide in vascular diseases: implications for treatment. Drug Des Devel Ther. 2013;8:49–65. doi:10.2147/DDDT.S6762.; Harenberg J. Review of pharmacodynamics, pharmacokinetics and therapeutic properties of sulodexide. Med Res. 1998;18(1):1–20. doi:10.1002/(SICI)1098-1128(199801)18:13.0.CO;2-4.; Milani M.R., Busutti L., Breccia A. Pharmacokinetics of sulodexide evaluation from 131-labelled fast-moving heparin after single intravenous and oral administration on man at different doses. Brit J Clin Res. 1992;3:161–178.; Carroll B.J., Piazza G., Goldhaber S.Z. Sulodexide in Venous Disease. J Thromb Haemost. 2019;17(1):31–38. doi:10.1111/jth.14324.; Cosmi B., Cini M., Legnani C., Pancani C., Calanni F., Coccheri S. Additive thrombin inhibition by fast moving heparin and dermatan sulfate explains the anticoagulant effect of sulodexide, a natural mixture of glycosaminoglycans. Thromb Res. 2003;109(5–6):333–339. doi:10.1016/S00493848(03)00246-9.; Mauro M., Ferraro G., Palmieri G.C. Profibrinolytic and antithrombotic effects of sulodexide oral administration: a double-blind, cross-over, placebocontrolled study. Curr Ther Res. 1992;51:342–350.; Cerletti C., Rajtar G., Marchi E., De Gaetano G. Interaction between glycosaminoglycans, platelets, and leukocytes. Semin Thromb Hemost. 1994;20(3):245–253. doi:10.1055/s-2007-1001909.; Young E. The anti-inflammatory effects of heparin and related compounds. Thromb Res. 2008;122(6):743–752. doi:10.1016/j.thromres.2006.10.026.; Ligi D., Croce L., Mosti G., Raffetto J.D., Mannello F. Chronic venous insufficiency: Transforming growth factor-beta isoforms and soluble endoglin concentration in different states of wound healing. Int J Mol Sci. 2017;18(10):2206. doi:10.3390/ijms18102206.; Mannello F., Ligi D., Raffetto J.D. Glycosaminoglycan sulodexide modulates inflammatory pathways in chronic venous disease. Int Angiol. 2014;33(3):236–242. Availale at: https://www.ncbi.nlm.nih.gov/pubmed/24936532.; Mannello F., Ligi D., Canale M., Raffetto J.D. Sulodexide down-regulates the release of cytokines, chemokines, and leukocyte colony stimulating factors from human macrophages: role of glycosaminoglycans in inflammatory pathways of chronic venous disease. Curr Vasc Pharmacol. 2014;12(1):173–185. doi:10.2174/1570161111666131126144025.; Ciszewicz M., Polubinska A., Antoniewicz A., Suminska-Jasinska K., Breborowicz A. Sulodexide suppresses inflammation in human endothelial cells and prevents glucose cytotoxicity. Transl Res. 2009;153(3):118–123. doi:10.1016/j.trsl.2008.12.007.; Blich M., Golan A., Arvatz G., Sebbag A., Shafat I., Sabo E. et al. Macrophage activation by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression. Arterioscler Thromb Vasc Biol. 2013;33(2):e56– e65. doi:10.1161/ATVBAHA.112.254961.; Andreozzi G.M. Role of sulodexide in the treatment of CVD. Int Angiol. 2014;33(3):255–262.; Mannello F., Medda V., Ligi D., Raffetto J.D. Glycosaminoglycan sulodexide inhibition of MMP-9 gelatinase secretion and activity: possible pharmacological role against collagen degradation in vascular chronic diseases. Curr Vasc Pharmacol. 2013;11(3):354–365. doi:10.2174/1570161111311030010.; Ligi D., Mosti G., Croce L., Raffetto J.D., Mannello F. Chronic venous disease – part II: Proteolytic biomarkers in wound healing. Biochim Biophys Acta (BBA). 2016;1862(10):1900–1908. doi:10.1016/j.bbadis.2016.07.011.; Meissner M.H., Eklof B., Smith P.C., Dalsing M.C., DePalma R.G., Gloviczki P. et al. Secondary chronic venous disorders. J Vasc Surg. 2007;46(6):S68S– S83. doi:10.1016/j.jvs.2007.08.048.; Chatterjee S. Endothelial mechanotransduction, redox signaling and the regulation of vascular inflammatory pathways. Front Physiol. 2018;9:1–16. doi:10.3389/fphys.2018.00524.; Bergan J.J., Schmid-Schönbein G.W., Coleridge Smith P.D., Nicolaides A.N., Boisseau M.R., Eklof B. Chronic venous disease. N Engl J Med. 2006;355:488–498. doi:10.1056/NEJMra055289.; Elleuch N., Zidi H., Bellamine Z., Hamdane A., Guerchi M., Jellazi N. Sulodexide in patients with chronic venous disease of the lower limbs: clinical efficacy and impact on quality of life. Adv Ther. 2016;33:1536– 1549. doi:10.1007/s12325-016-0359-9.; Raffetto J.D. Dermal pathology, cellular biology, and inflammation in chronic venous disease. Thromb Res. 2009;123:S66–S71. doi:10.1016/S0049-3848(09)70147-1.; Mansilha A., Sousa J. Pathophysiological mechanisms of chronic venous disease and implications for venoactive drug therapy. Int J Mol Sci. 2018;19(6):1–21. doi:10.3390/ijms19061669.; Kearon C., Kahn S.R., Agnelli G., Goldhaber S., Raskob G.E., Comerota A.J. Antithrombotic therapy for venous thromboembolic disease: American College of Chest physicians evidence-based clinical practice guidelines (8th ed.). Chest. 2008;133(6):454S–545S. doi:10.1378/chest.08-0658.; Engberink O., Rorije N.M., Lambers Heersprink H.J., Zeeuw D.D., Born van den B.-J.H., Vogt L. The blood pressure lowering potential of sulodexide – a systematic review and meta-analysis. Br J Clin Pharmacol. 2015;80(6):1245–1253. doi:10.1111/bcp.12722.; Кузнецова И.В. Роль преконцепционной эндотелиальной дисфункции в развитии акушерских осложнений. Медицинский алфавит. 2019;1(1):53–58. doi:10.33667/2078-5631-2019-1-1(376)-53-58.; https://www.med-sovet.pro/jour/article/view/5572

الاتاحة: https://www.med-sovet.pro/jour/article/view/5572
https://doi.org/10.21518/2079-701X-2020-3-68-73